Level of Immunological Protection against Diphtheria in the Population of Dnipropetrovsk Region
Background. Diphtheria — an infectious disease, the spread of which is limited by population post-vaccination immunity. In the system of epidemiological surveillance of diphtheria, for objective assessment and prediction of epidemic situation in low intensity of epidemic process of this infection, the serological control of immunity is crucial. The objective: prognosis of epidemic situation in terms of the risk of diphtheria outbreaks in Ukraine by the detection of population post-vaccination immunity against diphtheria in Dnipropetrovsk region and evaluation of the effectiveness of widespread vaccination. Materials and methods. 483 people aged 0 to 78 years were examined in total in 2015 (children — 234, adults — 249 persons). Evaluation of specific immunity against diphtheria was carried on with the following criteria: those with levels of antibodies 0.015–0.06 IU/mL should be considered as relatively protected; 0.1–0.5 IU/ml — with average level of protection; > 1.0 IU/ml — with high level of protection. Protective antibody titer should be considered the concentration of not less than 0.1 IU/ml. Results. It was established that the level of protective immunity against diphtheria was 69.5 %. Reliable level of immunological protection of children was 70.9 %, among adults — 68.3 %. None age group had sufficient threshold level of antitoxic immunity required to stop the transmission of diphtheria pathogen. Percentage of protected persons decreased with increasing age of people (both in children and adults). This situation may create conditions for outbreaks of diphtheria in Dnipropetrovsk region. Conclusions. The presented results indicate the importance of maintaining protective antibody levels through widespread immunization of children, as well as booster vaccination among adolescents and adults that will exclude the category of susceptible layer of the population.
Full Text:PDF (Українська)
Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A. Diphtheria in the Postepidemic Period, Europe, 2000–2009. Emerging Infectious Diseases. 2012;18(2):217-225. doi: 10.3201/eid1802.110987.
Chudna LM, Zadorozhna VI, Marychev IL, Demchyshyna IV. [Vaccine and its impact on the incidence of infections that are guided by means of specific immunization]. Preventive medicine. 2013;20(1-2):3-11. Ukranian.
Mariievskyi VF, Chudna LM. [The situation of diphtheria in Ukraine]. Preventive medicine. 2010;10(2):3-7. Ukranian.
Hladka OA, Sirenko IS. [Characteristics of the adult population of Ukraine scheplenosti be ill with diphtheria in 2000-2010]. Problems of military health care: Collected works. 2014;2(42):102-109. Ukranian.
Buts OR, Kramarev CO, Evtushenko VV, Vygovska OV, Kolibo DV, Romanjuk SI. [Antitoxic diphtheria immunity in children based on vaccina status]. Problems of military health care: Collected works. 2012;35:37-43. Ukranian.
Mostiuk AI, Prokopiv OV. [The consequences of violations routine vaccination against diphtheria, look at the recent past]. Current infection. 2009;3:33-41. Ukranian.
Swart EM, van Gageldonk PG, de Melker HE, van der Klis FR, Berbers GA, Mollema L. Long-Term Protection against Diphtheria in the Netherlands after 50 Years of Vaccination: Results from a Seroepidemiological Study. PLOS. 2016;11(2). e0148605. doi: 10.1371/journal.pone.0148605.
Krasiuk LS, Chudna LM, Svita VM, Hlushkevych TG, Holovchenko IY. [Current issues of prevention activities in diphtheria]. Preventive medicine. 2015;24(1-2):76-80. Ukranian.
Carbore RN, Pierard D, Huygen K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines (Basel). 2016;4(2). pii: E16. doi: 10.3390/vaccines4020016.
Bermejo-Martin JF, Avila-Alonso A, González-Rivera M, Tamayo E, Eiros JM, Almansa R. Postbooster antibodies from humans as source of diphtheria antitoxin. Emerg Infect Dis. 2016;22(7):1265–7.doi: 10.3201/eid2207.151670.
Zakikhany K, Efstratiou A. Diphtheria in Europe: current problems and new challenges. Future Microbiology. 2012;7(5):595-607. doi: 10.2217/fmb.12.24.
- There are currently no refbacks.
Copyright (c) 2017 ACTUAL INFECTOLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2017